adenine has been researched along with Virus Diseases in 20 studies
Virus Diseases: A general term for diseases caused by viruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Certain D-arabinosyl nucleosides, notably arabinosyl cytosine (araC) and arabinosyl adenine (araA), are useful in the treatment of certain leukemias and some DNA virus infections, respectively." | 4.75 | The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA). ( Cohen, SS, 1977) |
| "We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice." | 4.02 | Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. ( Busca, A; Candoni, A; Cattaneo, C; Dargenio, M; Facchinelli, D; Fanci, R; Farina, F; Laurenti, L; Lessi, F; Marchesi, F; Marchesini, G; Nadali, G; Pagano, L; Picardi, M; Prezioso, L; Spolzino, A; Tisi, MC; Trastulli, F; Verga, L; Visentin, A, 2021) |
| " Nature 1986;323:464-7], the acyclic nucleoside phosphonates have acquired a prominent therapeutic position: (i) cidofovir in the treatment of papilloma-, herpes-, adeno- and poxvirus infections, (ii) adefovir in the treatment of chronic hepatitis B virus (HBV) infections, and (iii) tenofovir in the treatment of human immunodeficiency virus (HIV) infections (AIDS)." | 3.74 | Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. ( De Clercq, E, 2007) |
| "To improve biosafety of clinical analysis, we used antiviral drugs of adefovir and tenofovir as model drugs and developed a safe pretreatment method combining sealing technique with direct injection technique." | 1.46 | A novel pretreatment method combining sealing technique with direct injection technique applied for improving biosafety. ( An, J; Du, C; Gao, JL; Jiang, Y; Li, M; Ma, H; Wang, X; Zhang, L, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hochman, MJ | 1 |
| Martin, DB | 1 |
| Zhou, Y | 1 |
| Kong, Y | 1 |
| Fan, W | 1 |
| Tao, T | 1 |
| Xiao, Q | 1 |
| Li, N | 1 |
| Zhu, X | 1 |
| Marchesini, G | 1 |
| Nadali, G | 1 |
| Facchinelli, D | 1 |
| Candoni, A | 1 |
| Cattaneo, C | 1 |
| Laurenti, L | 1 |
| Fanci, R | 1 |
| Farina, F | 1 |
| Lessi, F | 1 |
| Visentin, A | 1 |
| Marchesi, F | 1 |
| Prezioso, L | 1 |
| Spolzino, A | 1 |
| Tisi, MC | 1 |
| Trastulli, F | 1 |
| Picardi, M | 1 |
| Verga, L | 1 |
| Dargenio, M | 1 |
| Busca, A | 1 |
| Pagano, L | 1 |
| Tang, L | 1 |
| Wei, X | 1 |
| Li, T | 1 |
| Chen, Y | 1 |
| Dai, Z | 1 |
| Lu, C | 1 |
| Zheng, G | 1 |
| Manners, O | 1 |
| Baquero-Perez, B | 1 |
| Whitehouse, A | 1 |
| De Clercq, E | 5 |
| Chandra, G | 1 |
| Moon, YW | 1 |
| Lee, Y | 1 |
| Jang, JY | 1 |
| Song, J | 1 |
| Nayak, A | 1 |
| Oh, K | 1 |
| Mulamoottil, VA | 1 |
| Sahu, PK | 1 |
| Kim, G | 1 |
| Chang, TS | 1 |
| Noh, M | 1 |
| Lee, SK | 1 |
| Choi, S | 1 |
| Jeong, LS | 1 |
| Wang, X | 1 |
| Gao, JL | 1 |
| Du, C | 1 |
| An, J | 1 |
| Li, M | 1 |
| Ma, H | 1 |
| Zhang, L | 1 |
| Jiang, Y | 1 |
| Liu, C | 1 |
| Chen, Q | 1 |
| Yang, M | 1 |
| Schneller, SW | 1 |
| Avola, R | 1 |
| Castro, A | 1 |
| Ricceri, G | 1 |
| Cohen, SS | 1 |
| Mollica, F | 1 |
| Pavone, L | 1 |
| Nuciforo, G | 1 |
| Sorge, G | 1 |
| Pavan-Langston, D | 1 |
| Dohlman, CH | 1 |
| Weinstein, L | 1 |
| Chang, TW | 1 |
| Kaufman, HE | 1 |
| López, DM | 1 |
| Sigel, MM | 1 |
| Beasley, AR | 1 |
| Dietrich, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression[NCT01387022] | 59 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference between 12 months and randomisation CD4+ count was calculated and then summarised (NCT01387022)
Timeframe: Measured at 12 months post ART initiation
| Intervention | cells/uL (Median) |
|---|---|
| Tenofovir-containing Regimen | 217 |
| Tenofovir-sparing Regimen | 174 |
(NCT01387022)
Timeframe: From randomisation until either time of termination or time of death
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir-containing Regimen | 7 |
| Tenofovir-sparing Regimen | 12 |
(NCT01387022)
Timeframe: From randomisation until either time of termination or time of death
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir-containing Regimen | 1 |
| Tenofovir-sparing Regimen | 1 |
Treatment failure is defined as viral load > 50 copies/ml, antiretroviral regimen changes for treatment failure or death (NCT01387022)
Timeframe: 12 months post ART intiation or until time of death
| Intervention | participants (Number) |
|---|---|
| Tenofovir-containing Regimen | 4 |
| Tenofovir-sparing Regimen | 5 |
9 reviews available for adenine and Virus Diseases
| Article | Year |
|---|---|
Principles of RNA methylation and their implications for biology and medicine.
Topics: Adenine; AlkB Homolog 5, RNA Demethylase; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Hu | 2020 |
Emerging Perspectives of RNA
Topics: Adaptive Immunity; Adenine; Autoimmune Diseases; Dendritic Cells; Humans; Immunity, Innate; Methylat | 2021 |
m
Topics: Adenine; Animals; Host-Pathogen Interactions; Humans; Methyltransferases; RNA Processing, Post-Trans | 2019 |
The Holý Trinity: the acyclic nucleoside phosphonates.
Topics: Adenine; Antiviral Agents; Cidofovir; Cytosine; Drug Therapy, Combination; Humans; Nucleosides; Orga | 2013 |
The discovery of antiviral agents: ten different compounds, ten different stories.
Topics: Acyclovir; Adenine; Antiviral Agents; Benzodiazepines; Benzylamines; Cidofovir; Cyclams; Cytosine; H | 2008 |
Nucleoside analogues as antiviral agents.
Topics: Acyclovir; Adenine; Animals; Antiviral Agents; Arabinonucleosides; Bromodeoxyuridine; Chemical Pheno | 1981 |
The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA).
Topics: Adenine; Adenosine Deaminase Inhibitors; Adenosine Monophosphate; Adenosine Triphosphate; Animals; A | 1977 |
Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Organophosphonates; | 1990 |
Ocular virus disease.
Topics: Adenine; Adolescent; Chickenpox; Child; Child, Preschool; Chorioretinitis; Conjunctivitis; Corneal U | 1973 |
1 trial available for adenine and Virus Diseases
| Article | Year |
|---|---|
A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.
Topics: Adenine; Adenoviridae Infections; Antiviral Agents; Arabinose; Clinical Trials as Topic; Drug Hypers | 1972 |
10 other studies available for adenine and Virus Diseases
| Article | Year |
|---|---|
Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2021 |
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Bacterial Infections; Case-Co | 2021 |
Structure-Activity Relationships of Neplanocin A Analogues as S-Adenosylhomocysteine Hydrolase Inhibitors and Their Antiviral and Antitumor Activities.
Topics: Adenine; Adenosine; Adenosylhomocysteinase; Animals; Antineoplastic Agents; Antiviral Agents; Cell L | 2015 |
A novel pretreatment method combining sealing technique with direct injection technique applied for improving biosafety.
Topics: Adenine; Antiviral Agents; Chromatography, High Pressure Liquid; Clinical Laboratory Techniques; Hum | 2017 |
C-3 halo and 3-methyl substituted 5'-nor-3-deazaaristeromycins: synthesis and antiviral properties.
Topics: Adenine; Adenosine; Antiviral Agents; Crystallography, X-Ray; Humans; Models, Molecular; Virus Disea | 2013 |
Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Hepacivirus; Hepatitis B virus; HIV; Humans | 2007 |
Activity of some enzymes involved in "adenylate cycle" in rat embryo cells infected with parvoviruses (X14, H-1).
Topics: Adenine; Aminohydrolases; Animals; Cells, Cultured; Embryo, Mammalian; Female; Parvoviridae; Pentosy | 1981 |
A case of cyclopia. Role of environmental factors.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Abnormalities, Severe Teratoid; Adenine; Anti-Bacterial | 1979 |
The chemotherapy of viral infections.
Topics: Acridines; Adenine; Amantadine; Amino Alcohols; Antiviral Agents; Arabinose; Benzoates; Coloring Age | 1973 |
Biochemical and morphologic studies of lymphocystis disease.
Topics: Adenine; Animal Diseases; Animals; Carbon Isotopes; Culture Techniques; DNA; Fish Diseases; Fishes; | 1969 |